Why did Dexcom (DXCM) stock move recently?

On 7/22/2026, Dexcom moved -4.4% — No company-specific news or filing explains the decline; Dexcom moved lower with the broader market or sector after trading near 52-week highs on positive G7 growth commentary. This is MarketChacha's decoded reason from filings and credible news; it is education, not buy/sell advice.

Is Dexcom (DXCM) overvalued or fairly valued?

MarketChacha shows Dexcom's valuation in context — a trailing P/E of about 39.6, a forward P/E of about 28.4, a price-to-book of about 12.8 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

Does Dexcom's reported profit turn into cash?

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash. MarketChacha computes this cash-conversion check (1.63×) from reported figures — education, not a rating.

What is Dexcom's revenue?

Dexcom reported revenue of $4.7B for FY2025, with net profit of $836.3M, per official filings.

What is the share price of Dexcom (DXCM)?

Dexcom last traded at $91.20 (+1.6% on the day), as of 8/18/2026 — a delayed quote shown for education, not investment advice.

Dexcom

DXCM · NASDAQ · Healthcare · United States

Snapshot

TickerDXCM

ExchangeNASDAQ

SectorHealthcare

IndustryMedical Devices

CountryUnited States

Employees11,000

HeadquartersSan Diego, United States

Websitewww.dexcom.com

Filings tracked18

About Dexcom

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Who owns it

Insiders0.3%
Institutions99.7%
Public & other0.0%

1,445 institutional holders

Ownership breakdown from public market data.

Top holders

Blackrock Inc.10.13%
Vanguard Capital Management LLC6.68%
Vanguard Portfolio Management LLC5.21%
State Street Corporation4.87%
BAILLIE GIFFORD & CO3.92%
Invesco Ltd.3.62%
Geode Capital Management, LLC3.29%
Alliancebernstein L.P.3.10%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

No major accounting red flags in the fundamentals we have — profit is backed by cash and returns look healthy.

Cash conversion1.63×

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash.

Net margin trend14.9% → 17.9%

Margin has expanded by about 3.0 points — the business is getting more profitable.

Return on equity30.5%

Latest ROE of 30.5% — capital is generating a healthy return.

Growth qualityrev 13% · PAT 24%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $1.4B · EPS 0.73

Est. earnings growth +7.9%

Next fiscal year

Rev $5.8B · EPS 3.12

Est. earnings growth +17.4%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2025)

$4.7B

Net margin

17.9%

ROE

30.5%

Revenue CAGR (2y)

+13.4%

Profit CAGR (2y)

+24.3%

EPS (FY2025)

2.09

Net profit (FY2025)

$836.3M

Ask MarketChacha about DXCM

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Why it moved

Jul 22, 2026
No company-specific news or filing explains the decline; Dexcom moved lower with the broader market or sector after trading near 52-week highs on positive G7 growth commentary.
· confidence: low

Daily moves with the verified reason behind them. Education only — not investment advice.

On MarketChacha

Posts about DXCM

Why did Dexcom (DXCM) jump ~11% today?c/usmarkets · 7/31/2026▲ 0

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$4.7B	$836.3M	2.09	17.9%	30.5%
FY2024	$4.0B	$576.2M	1.42	14.3%	27.4%
FY2023	$3.6B	$541.5M	1.30	14.9%	26.2%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q2	$1.3B	$249.1M	0.64	19.0%
2026Q1	$1.2B	$199.5M	0.51	16.7%
2025Q3	$1.2B	$283.8M	0.70	23.5%
2025Q2	$1.2B	$179.8M	0.45	15.5%
2025Q1	$1.0B	$105.4M	0.27	10.2%
2024Q3	$994.2M	$134.6M	0.34	13.5%
2024Q2	$1.0B	$143.5M	0.35	14.3%
2024Q1	$921.0M	$146.4M	0.36	15.9%
2023Q3	$975.0M	$120.7M	0.29	12.4%
2023Q2	$871.3M	$115.9M	0.28	13.3%
2023Q1	$741.5M	$48.6M	0.12	6.6%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

8-K — Results of operations, Exhibits
SEC7/30/2026material
10-Q filing
SEC7/30/2026
8-K — Shareholder vote results
SEC5/28/2026material
8-K — Reg FD disclosure, Other events
SEC5/15/2026material
8-K — Results of operations, Exhibits
SEC4/30/2026material
10-Q filing
SEC4/30/2026
8-K — Executive/director change, Exhibits
SEC3/2/2026material
8-K — Executive/director change, Reg FD disclosure, Exhibits
SEC2/26/2026material
8-K — Results of operations, Exhibits
SEC2/12/2026material
10-K filing
SEC2/12/2026
8-K — Results of operations, Exhibits
SEC1/12/2026material

2025

8-K — Executive/director change, Exhibits
SEC12/22/2025material
8-K — Results of operations, Exhibits
SEC10/30/2025material
10-Q filing
SEC10/30/2025
8-K — Executive/director change, Reg FD disclosure, Exhibits
SEC10/27/2025material
8-K — Executive/director change
SEC9/16/2025material
8-K — Results of operations, Executive/director change, Exhibits
SEC7/30/2025material
10-Q filing
SEC7/30/2025

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.